Afya Limited (NASDAQ:AFYA – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 978,300 shares, a growth of 13.1% from the September 30th total of 865,100 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 140,200 shares, the short-interest ratio is presently 7.0 days.
Afya Price Performance
Afya stock opened at $16.78 on Wednesday. Afya has a 12-month low of $14.64 and a 12-month high of $22.48. The stock has a market cap of $1.57 billion, a P/E ratio of 15.68, a PEG ratio of 0.45 and a beta of 0.92. The company has a 50-day moving average price of $16.74 and a 200 day moving average price of $17.23. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.40.
Afya (NASDAQ:AFYA – Get Free Report) last released its quarterly earnings data on Thursday, August 15th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.06. Afya had a net margin of 18.12% and a return on equity of 18.82%. The firm had revenue of $155.40 million during the quarter, compared to analysts’ expectations of $151.83 million. Sell-side analysts anticipate that Afya will post 1.52 earnings per share for the current year.
Institutional Investors Weigh In On Afya
Analysts Set New Price Targets
Separately, UBS Group started coverage on shares of Afya in a research report on Friday, August 30th. They issued a “neutral” rating and a $19.50 target price for the company.
View Our Latest Research Report on Afya
About Afya
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
Featured Stories
- Five stocks we like better than Afya
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Using the MarketBeat Dividend Tax Calculator
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Upcoming IPO Stock Lockup Period, Explained
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.